104 related articles for article (PubMed ID: 6298933)
21. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
Vcev A; Stimac D; Vceva A; Rubinić M; Ivandić A; Ivanis N; Horvat D; Volarić M; Karner I
Acta Med Croatica; 1997; 51(3):171-4. PubMed ID: 9248117
[TBL] [Abstract][Full Text] [Related]
22. Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
Bardhan KD; Cherian P; Jones RB; Vaishnavi A; Manek S; Bishop A; Polak J; Brooks A; Morris P; Thompson M; D'Silva J; Parkin S; Patterson J; Gillon KR
Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):515-9. PubMed ID: 9513825
[TBL] [Abstract][Full Text] [Related]
23. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
24. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
Bohmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Tuynman HA; Voskuil JH; Devillé WL; Meuwissen SG
Am J Gastroenterol; 1997 Sep; 92(9):1475-9. PubMed ID: 9317066
[TBL] [Abstract][Full Text] [Related]
25. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies.
Sontag SJ; O'Connell S; Khandelwal S; Greenlee H; Schnell T; Nemchausky B; Chejfec G; Miller T; Seidel J; Sonnenberg A
Am J Gastroenterol; 2003 May; 98(5):987-99. PubMed ID: 12809818
[TBL] [Abstract][Full Text] [Related]
26. [Our experience in the treatment of reflux esophagitis with histamine H2 receptor antagonists].
Cappelli J; Morobe J; Van Laethem A; Musin L
Acta Chir Belg; 1983; 83(6):440-3. PubMed ID: 6318487
[TBL] [Abstract][Full Text] [Related]
27. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
[TBL] [Abstract][Full Text] [Related]
28. [Role of ranitidine in the treatment of gastroesophageal reflux and its complications].
Mainguet P
Rev Med Suisse Romande; 1995 Oct; 115(10):781-8. PubMed ID: 7501930
[No Abstract] [Full Text] [Related]
29. [Usefulness of ranitidine in the treatment of esophagitis caused by gastro-esophageal acid reflux].
Nervi M; Conte M; Buttitta F; Spisni R
Minerva Dietol Gastroenterol; 1989; 35(3):195-9. PubMed ID: 2689913
[TBL] [Abstract][Full Text] [Related]
30. Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis.
Masci E; Testoni PA; Passaretti S; Guslandi M; Tittobello A
Drugs Exp Clin Res; 1985; 11(10):687-92. PubMed ID: 3915459
[TBL] [Abstract][Full Text] [Related]
31. Comparison of omeprazole and ranitidine in the treatment of reflux esophagitis.
Blum AL; Riecken EO; Dammann HG; Schiessel R; Lux G; Wienbeck M; Rehner M; Witzel L
N Engl J Med; 1986 Mar; 314(11):716. PubMed ID: 3513011
[No Abstract] [Full Text] [Related]
32. Omeprazole in patients with mild or moderate reflux esophagitis induces lower relapse rates than ranitidine during maintenance treatment.
Annibale B; Franceschi M; Fusillo M; Beni M; Cesana B; Delle Fave G
Hepatogastroenterology; 1998; 45(21):742-51. PubMed ID: 9684126
[TBL] [Abstract][Full Text] [Related]
33. Healing and relapse of reflux esophagitis during treatment with ranitidine.
Koelz HR; Birchler R; Bretholz A; Bron B; Capitaine Y; Delmore G; Fehr HF; Fumagalli I; Gehrig J; Gonvers JJ
Gastroenterology; 1986 Nov; 91(5):1198-205. PubMed ID: 3530865
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of sucralfate in reflux oesophagitis.
Tytgat GN
Scand J Gastroenterol Suppl; 1987; 140():29-31. PubMed ID: 3328282
[TBL] [Abstract][Full Text] [Related]
35. [Effect of oxmetidine and ranitidine on reflux behavior in patients with esophagitis].
Weiser HF; Gubernatis G; Siewert JR
Z Gastroenterol; 1983 Oct; 21(10):580-4. PubMed ID: 6139923
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of the effect of placebo on the outcome of medically treated reflux esophagitis.
Pace F; Maconi G; Molteni P; Minguzzi M; Bianchi Porro G
Scand J Gastroenterol; 1995 Feb; 30(2):101-5. PubMed ID: 7732329
[TBL] [Abstract][Full Text] [Related]
37. Factors predicting relapse during maintenance treatment with famotidine in patients with healed reflux esophagitis. Dutch Esophagitis Study Group.
Wesdorp IC; Dekker W; Festen HP
Clin Ther; 1997; 19(5):1048-57. PubMed ID: 9385492
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy of sucralfate and ranitidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis.
Vermeijden JR; Tytgat GN; Schotborgh RH; Dekker W; vd Boomgaard DM; van Olffen GH; Schrijver M; Vosmaer GD; Dekkers CP
Scand J Gastroenterol; 1992; 27(2):81-4. PubMed ID: 1561531
[TBL] [Abstract][Full Text] [Related]
39. H2 antagonists in the treatment of reflux esophagitis: a critical analysis.
Stalnikowicz-Darvasi R
Am J Gastroenterol; 1989 Mar; 84(3):245-8. PubMed ID: 2563926
[TBL] [Abstract][Full Text] [Related]
40. Maintenance therapies for reflux esophagitis.
Grey MR
N Engl J Med; 1996 Feb; 334(9):600-1. PubMed ID: 8569838
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
